Treatment of mood and stress-related disorder

Raz Yirmiya, Tirzah Kreisel         

Publication Number              Filing Date                     Grant Date                Status

US 9950036B2                    2014-08-20                    2018-04-24                 Grant

A pharmaceutical composition and method for treating or attenuating a mood or stress-related disorder in a subject having normal or low inflammatory state is provided. In some embodiments, the pharmaceutical composition and method of the invention comprise activating or stimulating microglia for treatment of mood or stress-related disorder.

Treatment of mood and stress-related disorder (Contionuation in part)

Raz Yirmiya       

Publication Number                Filing Date                     Grant Date              Status

US20180230223A1                2018-03-23                   2020-04-20              Grant

A method for treating or attenuating a major depressive disorder (MDD) in a subject having plasma C-reactive protein (CRP) levels lower than 3 mg/L, the method comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a CX3C receptor 1 (CX3CR1) inhibitor and at least one pharmaceutically acceptable carrier or diluent.

Microglia modulators for use in treatment of depression

Raz Yirmiya       

Publication Number                Filing Date                  Publication Date          Status

WO201986559A1                   2018-03-27                   2019-03-10              Application

The present invention related to methods for treating a depression condition in a subject, including administering to the subject at least one microglial modulator or a combination thereof. Further provided are methods using a microglial modulator(s) in combination with non-invasive brain stimulation (NIBS), such as electroconvulsive therapy (ECT).

Antisense oligonucleotides against AChE in the treatment of gastrointestinal inflammation disorders

Hermona Soreq, Raz Yirmiya         

Publication Number                Filing Date                  Publication Date .          Status

US8722876B2                        2013-05-22                   2014-05-13                  Grant 

AChE antisense oligonucleotides are used as antiinflammatory agents, such oligonucleotides preferably having the sequence of SEQ ID NO:1 and SEQ ID NO:7. Methods of treatment of inflammatory conditions, as well as fever, and particularly inflammation of the gastrointestinal tract, are described.

AChE antisense deoxyoligonucleotide as an anti-inflammatory agent    

Hermona Soreq, Amir Dori Itzhak Wirguin Gal Ifergane, Raz Yirmiya

Publication Number                Filing Date                  Publication Date .            Status

US20130018081A1               2003-10-26                   2013-01-17                   Application

The present invention provides a novel use for AChE antisense oligonucleotides as anti-inflammatory agents, wherein said oligonucleotides are preferably as denoted by SEQ. ID. NO:1, SEQ. ID. NO:2 and SEQ. ID. NO:7. Described are pharmaceutical compositions for the treatment of inflammatory conditions comprising as active agent said AChE antisense oligonucleotides. 

Method for assessing trait anxiety by determining cholinergic status     

Hermona Soreq Ella Sklan Raz Yirmiya Keren Ailon Irit Shapira-Lichter

Publication Number                Filing Date                  Publication Date .           Status

US 7494783                            2006-04-10                  2009-02-24                 Application

The invention provides methods/kits for assessing levels of trait or state anxiety in a subject by comparing genotypes and/or expression patterns at the ACHE, PON1 and/or BChE genes to the genotype and/or expression pattern of the genes in a reference population whose genotype and/or expression pattern of the genes is known or by correlating AChE levels activity to those of PON.

Composition comprising cannabinoids, terpenes, and flavonoids for treating depression

Publication Number                Filing Date                  Publication Date .           Status

IL2021/050865                        2020-07-20                                                        PCT Application

The present invention relates to methods and compositions for treating a mood disorder in a subject in need thereof, providing a microglia suppressive formulation based on a composition of a first cannabinoid, and at least one additional therapeutic compound selected from: at least one cannabinoid being different from the first cannabinoid, a terpene, a flavonoid, and any combination thereof.  The presented methods and compositions are particularly suitable for a subject afflicted with depression who is characterized as having activated microglial inflammatory status.              

See also Raz Yirmiya's site at Yissum (Research Development Company of the Hebrew University of Jerusalem Ltd.): https://covalentdata.com/institution/hebrew-university-of-jerusalem/port...